More than 5.3 million people suffer from diabetes in our country.To facilitate its adherence to treatment, avoid associated complications, such as hypoglycemia, and improve its feeling of independence is already available in Spain.The treatment of this pathology.
“This insulin, the first of a new generation, provides not only the control of the blood sugar level that patients need but also additional benefits specifically aimed at improving their quality of life.It is, without a doubt, an important step forward, because it is the only insulin with a flexible administration, that is, it offers people with diabetes the possibility of injecting it at any time, adapting to their needs.
In addition, Tresiba ® significantly reduces the risk of hypoglycemia, including nightMuñoz, endocrinologist at the San Cecilio de Granada University Hospital.Therefore, especially significant advance if one takes into account that hypoglycemia are the main risk that daily coexistence with diabetes entails.
Now, the Spanish Agency for Medicines and Health Products (AEMPS) has given the green light to insulin Degludec Tresiba ® and its reimbursement is approved by the National Health System, a basal insulin that is administered once a day and is indicated for theTreatment of people with type 1 diabetes and type 2 that have more than a year.
The novelty that Tresiba ® contributes in its mechanism of action, becoming the first insulin that provides a duration of action beyond 42 hours that successfully reduces the level of long -term blood glucose (HBA1C) and the riskof hypoglycemia, with rates significantly superior to insulin glargine.
“Having this new therapeutic option helps both doctors and patients to achieve the disease control objectives.The safety, efficacy and flexibility it provides is a clear progress not only for the freedom that it contributes to patients but because they also have a reduced risk of hypoglycemia, a side effect of insulin treatment that generates insecurity and fear.While for us, doctors, hypoglycemia is a brake when starting or intensifying antidiabetic treatments.In this way, the main needs and demands of doctors and patients are covered, ”says Dr. Francisco Merino, head of the Endocrinology and Nutrition Service of the La Fe Valencia University Hospital.
As Dr. Francisco Pajuelo, medical director of Novo Nordisk details, “This therapeutic innovation is another example of our firm commitment to diabetes.We have marked the way to follow in the new treatments in relation to glycemic control and with the improvement of the quality of life.And our commitment is to continue working in this line to facilitate daily life to Persons with diabetes and do not have to live thinking about the disease.We have managed to develop an insulin that adapts to the patient's life instead that the patient has to adapt his life to the administration of insulin. ”
experience in clinical trials
Insulin Degludec Tresiba ® is endorsed by an extensive clinical trial program, Begin, which has had the participation of more than 11,000 patients.In different comparative studies between insulin swallow and insulin glargine, people treated with insulin swallower achieved similar reductions in long blood glucose levelTerm (HBA1C) and a numerically greater reduction of fasting plasma glucose, using a lower dose of insulin dose in most tests.
"News of great value for the specialists who treat patients with diabetes, who also showed greater satisfaction and preference for insulin swallow against insulin glargina," explains Dr. Muñoz.Likewise, patients who received insulin Degludec also reported less cases of night hypoglycemia, so “the results support this new insulin from which adults, young people and children will be able to benefit.In the latter, hypoglycemia are especially compromising, especially nightlife.His brain is in development and episodes of this type can have serious long -term consequences. ”
hypoglycemia: risks and consequences
In Dr. Merino's words, “we know that hypoglycemia imply instability in the control of the disease, being a clear obstacle to optimizing metabolic control, and this will have an impact on the appearance and progression of more or less serious health complications.If they occur repetitively, they can affect the neurological system and, in some cases, become a precipitating dementia factor.There are also studies that relate them to an increase in the risk of cardiovascular diseases. ”
As Dr. Pajuelo confirms, “the consequences of hypoglycemia for the health system are evident.First, the treatment of hypoglycemia already involves a consumption of resources but, without a doubt, the fundamental problem is the cost of treatment to address the clinical problems derived from it ”.
